JP7325407B2 - ガレクチン－３タンパク質に対する特異的結合分子 - Google Patents

ガレクチン－３タンパク質に対する特異的結合分子 Download PDF

Info

Publication number
JP7325407B2
JP7325407B2 JP2020519382A JP2020519382A JP7325407B2 JP 7325407 B2 JP7325407 B2 JP 7325407B2 JP 2020519382 A JP2020519382 A JP 2020519382A JP 2020519382 A JP2020519382 A JP 2020519382A JP 7325407 B2 JP7325407 B2 JP 7325407B2
Authority
JP
Japan
Prior art keywords
specific binding
binding molecule
seq
fusion protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500874A5 (enExample
JP2021500874A (ja
Inventor
フォンテーヌ，アレクサンドル
モンドン，フィリップ
ラロシュ－トレノー，ジェニー
ジャコバン－ヴァラ，マリ－ジョゼ
チェルッティ，マルティーヌ
クロフェント－サンチェス，ジゼル
ロレンツァート，シリル
ヘマドウ，オドレイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of JP2021500874A publication Critical patent/JP2021500874A/ja
Publication of JP2021500874A5 publication Critical patent/JP2021500874A5/ja
Application granted granted Critical
Publication of JP7325407B2 publication Critical patent/JP7325407B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020519382A 2017-10-05 2018-10-05 ガレクチン－３タンパク質に対する特異的結合分子 Active JP7325407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306337.1A EP3466975A1 (en) 2017-10-05 2017-10-05 A specific binding molecule directed against galectin-3 protein
EP17306337.1 2017-10-05
PCT/EP2018/077131 WO2019068863A1 (en) 2017-10-05 2018-10-05 SPECIFIC BINDING MOLECULE DIRECTED AGAINST GALECTIN-3 PROTEIN

Publications (3)

Publication Number Publication Date
JP2021500874A JP2021500874A (ja) 2021-01-14
JP2021500874A5 JP2021500874A5 (enExample) 2021-10-28
JP7325407B2 true JP7325407B2 (ja) 2023-08-14

Family

ID=60119974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519382A Active JP7325407B2 (ja) 2017-10-05 2018-10-05 ガレクチン－３タンパク質に対する特異的結合分子

Country Status (4)

Country Link
US (1) US11091552B2 (enExample)
EP (2) EP3466975A1 (enExample)
JP (1) JP7325407B2 (enExample)
WO (1) WO2019068863A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP7539834B2 (ja) 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) * 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
US12655221B2 (en) 2020-12-08 2026-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN115746134A (zh) * 2021-10-15 2023-03-07 深圳市睿盟创新生物科技有限公司 半乳糖凝集素-3的免疫测定
US20230279120A1 (en) * 2021-11-09 2023-09-07 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases
JP2026523670A (ja) * 2024-03-08 2026-07-14 サンメッド セラピューティック リミテッド 抗ガレクチン３抗体ならびに癲癇および関連疾患におけるその使用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112559A1 (en) 2007-03-09 2008-09-18 Regents Of The University Of California Suppression of galectin-3 for treating an inflammatory condition
JP2010533850A (ja) 2007-07-19 2010-10-28 ビオメリュー 結腸直腸癌のインビトロ診断のためのアミノアシラーゼ１・アッセイ方法
JP2012507724A (ja) 2008-10-29 2012-03-29 ビージー メディシン， インコーポレイテッド ガレクチン−３の免疫アッセイ
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
JP2017512205A (ja) 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US20090318308A1 (en) 2006-05-30 2009-12-24 Millegen Highly diversified antibody libraries

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112559A1 (en) 2007-03-09 2008-09-18 Regents Of The University Of California Suppression of galectin-3 for treating an inflammatory condition
JP2010533850A (ja) 2007-07-19 2010-10-28 ビオメリュー 結腸直腸癌のインビトロ診断のためのアミノアシラーゼ１・アッセイ方法
JP2012507724A (ja) 2008-10-29 2012-03-29 ビージー メディシン， インコーポレイテッド ガレクチン−３の免疫アッセイ
JP2017512205A (ja) 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof

Also Published As

Publication number Publication date
US11091552B2 (en) 2021-08-17
EP3692067A1 (en) 2020-08-12
EP3466975A1 (en) 2019-04-10
WO2019068863A1 (en) 2019-04-11
JP2021500874A (ja) 2021-01-14
US20210079101A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US11091552B2 (en) Specific binding molecule directed against galectin-3 protein
RU2746812C1 (ru) Способы и композиции для лечения амилоидозов
Thomas et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
JP4869074B2 (ja) 抗体
US20030064069A1 (en) Specific binding members for TGFbeta1
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
ZA200505114B (en) Chimeric and humanized antibodies to a5p"1 integrin that modulate angiogenesis
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
WO2004041863A2 (en) Single domain antibodies directed against interferon- gamma and uses therefor
JP2024512858A (ja) 抗ｔｓｌｐナノ抗体およびその使用
CN118027195B (zh) 亲和力成熟的mica抗体及其应用
CN103415619B (zh) 抗-c-met抗体及其使用方法
MXPA02004244A (es) Reactivos y metodos para el diagnostico, la formacion de imagenes y el tratamiento del padecimiento de la ateroesclerosis..
WO2026021378A1 (zh) 抗FRα抗体或抗原结合片段、抗体偶联药物及其应用
JP2026510185A (ja) Ｆａｓリガンドに対して特異的なモノクローナル抗体およびその使用
US12161889B2 (en) Blood brain barrier (BBB)-selective antibodies and methods of use thereof to target agents to the BBB
JP2022541765A (ja) 抗ｇｒｐ７８抗体およびその使用方法
EP4442275A1 (en) Anti-type ii collagen antibodies
WO2025257181A1 (en) Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
EP3980448A1 (en) Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
HK40035170A (en) Methods and compositions for treatment of amyloid deposition diseases
JPWO2001023431A1 (ja) ガングリオシドｇｍ２に対する抗体の誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230801

R150 Certificate of patent or registration of utility model

Ref document number: 7325407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150